340 related articles for article (PubMed ID: 20974285)
21. [Chemotherapeutic effectiveness of stibomen in experimental leishmaniasis and trypanosomiasis].
Pershin GN; Moskalenko NIu
Med Parazitol (Mosk); 1967; 36(4):422-7. PubMed ID: 5612807
[No Abstract] [Full Text] [Related]
22. New chemotherapeutic strategies against malaria, leishmaniasis and trypanosomiases.
Zucca M; Scutera S; Savoia D
Curr Med Chem; 2013; 20(4):502-26. PubMed ID: 23210775
[TBL] [Abstract][Full Text] [Related]
23. Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis.
Njoroge M; Njuguna NM; Mutai P; Ongarora DS; Smith PW; Chibale K
Chem Rev; 2014 Nov; 114(22):11138-63. PubMed ID: 25014712
[No Abstract] [Full Text] [Related]
24. Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia.
Krauth-Siegel RL; Bauer H; Schirmer RH
Angew Chem Int Ed Engl; 2005 Jan; 44(5):690-715. PubMed ID: 15657967
[TBL] [Abstract][Full Text] [Related]
25. Trypanosomiasis and leishmaniasis: between the idea and the reality of control.
Denise H; Matthews K; Lindergård G; Croft S; Barrett MP
Parasitol Today; 1999 Feb; 15(2):43-5. PubMed ID: 10234181
[No Abstract] [Full Text] [Related]
26. The therapeutic potential of metal-based antimalarial agents: implications for the mechanism of action.
Biot C; Castro W; Botté CY; Navarro M
Dalton Trans; 2012 Jun; 41(21):6335-49. PubMed ID: 22362072
[TBL] [Abstract][Full Text] [Related]
27. Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development.
Na-Bangchang K; Karbwang J
Fundam Clin Pharmacol; 2009 Aug; 23(4):387-409. PubMed ID: 19709319
[TBL] [Abstract][Full Text] [Related]
28. π-Delocalized Lipophilic Cations as New Candidates for Antimalarial, Antitrypanosomal and Antileishmanial Agents: Synthesis, Evaluation of Antiprotozoal Potency, and Insight into Their Action Mechanisms.
Takasu K
Chem Pharm Bull (Tokyo); 2016; 64(7):656-67. PubMed ID: 27373622
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and in vitro antiprotozoal evaluation of substituted phenalenone analogues.
Rosquete LI; Cabrera-Serra MG; Piñero JE; Martín-Rodríguez P; Fernández-Pérez L; Luis JG; McNaughton-Smith G; Abad-Grillo T
Bioorg Med Chem; 2010 Jun; 18(12):4530-4. PubMed ID: 20472446
[TBL] [Abstract][Full Text] [Related]
30. Metal- and metalloid-containing drugs for the treatment of trypanosomatid diseases.
Colotti G; Fiorillo A; Ilari A
Front Biosci (Landmark Ed); 2018 Jan; 23(5):954-966. PubMed ID: 28930584
[TBL] [Abstract][Full Text] [Related]
31. A review of QSAR studies to discover new drug-like compounds actives against leishmaniasis and trypanosomiasis.
Castillo-Garit JA; Abad C; Rodríguez-Borges JE; Marrero-Ponce Y; Torrens F
Curr Top Med Chem; 2012; 12(8):852-65. PubMed ID: 22352913
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases.
Shakur Y; de Koning HP; Ke H; Kambayashi J; Seebeck T
Handb Exp Pharmacol; 2011; (204):487-510. PubMed ID: 21695653
[TBL] [Abstract][Full Text] [Related]
33. [New drugs for the treatment of human parasitic protozoa].
Dupouy-Camet J
Parassitologia; 2004 Jun; 46(1-2):81-4. PubMed ID: 15305692
[TBL] [Abstract][Full Text] [Related]
34. Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.
Nagle AS; Khare S; Kumar AB; Supek F; Buchynskyy A; Mathison CJ; Chennamaneni NK; Pendem N; Buckner FS; Gelb MH; Molteni V
Chem Rev; 2014 Nov; 114(22):11305-47. PubMed ID: 25365529
[No Abstract] [Full Text] [Related]
35. Kinetoplastida: new therapeutic strategies.
Croft SL
Parasite; 2008 Sep; 15(3):522-7. PubMed ID: 18814734
[TBL] [Abstract][Full Text] [Related]
36. Rational approaches for drug designing against leishmaniasis.
Shukla AK; Singh BK; Patra S; Dubey VK
Appl Biochem Biotechnol; 2010 Apr; 160(8):2208-18. PubMed ID: 19756413
[TBL] [Abstract][Full Text] [Related]
37. The necessity to develop drugs against parasitic diseases.
Kaiser A; Gottwald A; Wiersch C; Maier W; Seitz HM
Pharmazie; 2002 Nov; 57(11):723-8. PubMed ID: 12611273
[TBL] [Abstract][Full Text] [Related]
38. Therapy of vector-borne protozoan infections in nonendemic settings.
Bottieau E; Vekemans M; Van Gompel A
Expert Rev Anti Infect Ther; 2011 May; 9(5):583-608. PubMed ID: 21609269
[TBL] [Abstract][Full Text] [Related]
39. Novel molecular targets for antimalarial chemotherapy.
Jana S; Paliwal J
Int J Antimicrob Agents; 2007 Jul; 30(1):4-10. PubMed ID: 17339102
[TBL] [Abstract][Full Text] [Related]
40. Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review.
Cruz AK; de Toledo JS; Falade M; Terrão MC; Kamchonwongpaisan S; Kyle DE; Uthaipibull C
Curr Drug Targets; 2009 Mar; 10(3):178-92. PubMed ID: 19275555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
